Abstract
Developing predictive and transparent approaches to the analysis of metabolite profiles across patient cohorts is of critical importance for understanding the events that trigger or modulate traits of interest (e.g., disease progression, drug metabolism, chemical risk assessment). However, metabolites’ chemical structures are still rarely used in the statistical modeling workflows that establish these trait-metabolite relationships. Herein, we present a novel cheminformatics-based approach capable of identifying predictive, interpretable, and reproducible trait-metabolite relationships. As a proof-of-concept, we utilize a previously published case study consisting of metabolite profiles from non-small-cell lung cancer (NSCLC) adenocarcinoma patients and healthy controls. By characterizing each structurally annotated metabolite using both computed molecular descriptors and patient metabolite concentration profiles, we show that these complementary features enhance the identification and understanding of key metabolites associated with cancer. Ultimately, we built multi-metabolite classification models for assessing patients’ cancer status using specific groups of metabolites identified based on high structural similarity through chemical clustering. We subsequently performed a metabolic pathway enrichment analysis to identify potential mechanistic relationships between metabolites and NSCLC adenocarcinoma. This cheminformatics-inspired approach relies on the metabolites’ structural features and chemical properties to provide critical information about metabolite-trait associations. This method could ultimately facilitate biological understanding and advance research based on metabolomics data, especially with respect to the identification of novel biomarkers.
Highlights
The metabolome is an individual’s phenotype at the molecular level [1,2,3,4]
Subjects diagnosed with non-small-cell lung cancer (NSCLC) stage I-IV adenocarcinoma were recruited by the UC Davis Medical Center and Cancer Center Clinics
Gas chromatography time-of-flight (GCTOF) mass spectrometry untargeted metabolomics analysis was performed using plasma and serum samples collected from each patient
Summary
The metabolome is an individual’s phenotype at the molecular level [1,2,3,4]. Profiling metabolites (i.e., small molecule with molecular weight < 1500 Da) present in a given sample (e.g., serum, plasma, urine) enables in-depth investigations into various biochemical perturbations with internal (e.g., disease, drug metabolites, microbiome) and external (e.g., exposome, drugs) origins. The potential for certain metabolites to be discovered as disease biomarkers has resulted in a rapidly expanding body of metabolomics studies. Metabolomics has been used to search for biomarkers for colon cancer [5, 6], multiple sclerosis [7], and Alzheimer’s disease [8,9,10]. Drug discovery efforts routinely use metabolomics to study the efficacy, toxicity, and pharmacokinetic/pharmacodynamic properties of drug candidates and their metabolites [11].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.